Skip to content
Fear and GreedStocks35Crypto24
Start for free

Intuitive Surgical stock

ISRGNASDAQ

Intuitive Surgical, Inc., HealthcareISIN US46120E6023

$449.53▼ $0.51 (−0.1%)Closing price of 11 Nov 2026

76Score 76 out of 100, Strong

Turn on early warning

Price and trend

63 / 100

Price history

−21% in one year

The chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.

Long-term trend

Above the 200-day line: the price is 4.5% above it.

Trend change

Since March 2026 the 50-day line has been below the 200-day line; the trend has turned down.

Momentum

Normal: the price is neither overheated nor sold off (RSI 52).

Distance to the high

The price is 24% below its 52-week high. Largest decline in 20 years: 76% (April 2008 to March 2009).

Chart figures for advanced users
SMA 50$414.76
Average price of the last 50 trading days, shows the short-term trend.
SMA 200$430.11
Average price of the last 200 trading days, shows the long-term trend.
RSI (14)52
Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
MACDbelow the signal line
Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
Support$332.02
The lowest closing price of the last twelve months.
Resistance$592.85
The highest closing price of the last twelve months.
What would $1,000 in Intuitive Surgical have become?Return triangle for Intuitive Surgical
Market cap
$155.83B
Div. yield
no dividend
53.5
36.5
on earnings for the next twelve months ($12.31 per share)
Fair value
$278.35

Snapshot

Computed from the data by fixed rules, no AI

  • Intuitive Surgical, Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $155.83B, is the largest of 44 companies in its industry on MEQIRI.
  • In fiscal 2025 it reported revenue of $10.06B (up 20.5% year on year) and earnings of $2.86B (up 23%).
  • For fiscal 2026, analysts expect on average revenue of $11.93B (up 18.5%) and adjusted earnings per share of $11.25 (up 25.9%).
Show more
  • MEQIRI Score 76 out of 100 (Strong): rank 52 of 714 in Healthcare, median 53.
  • The P/E is 53.5 (Medical (Instruments & Supplies) median 34.8, own median of recent years 68.3).
  • Our model puts fair value at $278.35, with the price 61% above it.

In plain words

The numbers on this page in plain words, written by an AI

Strengths

  • More cash than debtCash $4.04B, financial debt $0.Stability 89
  • Growing faster than its industryRevenue up 18.2% a year since 2020, Medical (Instruments & Supplies) median 9.5%.Growth 92
  • Earnings per share growingUp 21.5% a year since 2020.Growth 92

Weaknesses

  • Above fair valuePrice 61% above the fair value of $278.35.Valuation 16
76/ 100
MEQIRI Score
Strong

Its standout strengths are fundamentals and growth, while momentum and valuation hold the score back.

Daily figure as of 12 Nov 2026

How the score is calculated

Score overview

Fundamentals are strong, with stable profits and strong cash generation.

Profit consistency100% of years
Cash conversion (free cash flow to earnings, 12 months)122%
ROIC (12 months)21.5%
Positive free cash flow100% of years
How this category is measured

Score history

The full history of up to 20 years comes with MEQIRI Pro.

See plans

Crash risk medium

How well MEQIRI warns

In the middle among stocks ranked 101 to 1,000.

From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.

What drives the risk

  • high growth grade (crashed more often in the backtest)

What lowers it

  • solid fundamentals

Valuation

Valuation signal

Significantly overvalued
Price
$449.53
Fair value
$278.35
Gap to fair value
+61%

In our model the price counts as cheap below $214.11 and expensive above $397.64 (uncertainty medium, based on the price swings of the past year).

The two parts of the fair value come to $264.26 (cash-flow model) and $292.44 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.

Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $254.57, at 7.8% it would be $314.16.

Valuation metrics

4.73
36.8
Fair value (model)
$278.35
Earnings part $292.44 (earnings per share $8.41 × 34.8)

Half from the cash-flow model, half from earnings times the industry P/E (34.8).

Calculate with your own assumptions

Company performance

This shows several years of history with an automatic assessment.

Revenue

20 years

In the twelve months to 30 Sep 2026, revenue rose 20.5% on the twelve months before. Revenue has grown strongly since 2006, at around 19% per year.

Margins

20 years
  • Gross margin
  • Operating margin
  • Net margin

In fiscal 2025: gross 66%, operating 29%, net 28%.

Debt & balance sheet

latest quarter
0.02
> 100x
3.33
Cash & equivalents
$4.04B

The balance sheet is solid, with low debt and comfortable interest coverage.

Earnings

Next earnings
28 Jan 2027in 77 days
Last reported
20 Oct 2026EPS reported $3.00 (expected $2.65)above expectations

Analyst estimates

Analysts have raised their 2026 earnings estimate by 4.1% since 15 Oct 2026.

Fiscal 202623 analysts
Earnings per share
$11.25+4.1%
Revenue
$11.93B+1.4%
Fiscal 202724 analysts
Earnings per share
$12.48+3.2%
Revenue
$13.35B+0.6%

MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.

Company outlook confirmed

Share price after the results: −11.2%

Da Vinci procedure growth of 13.5% to 15.5% for 2026 kept, closer to the midpoint, while US growth moderated versus early-year expectations.

Supporting passage from the call, verbatim
“In April, we forecast full year 2026 da Vinci procedure growth to be within a range of 13.5% to 15.5%. We are maintaining our forecast to be within this range with an expectation to be closer to the midpoint.”

The outlook is not part of the score and not a recommendation to buy or sell.

From the earnings call on 16 Jul 2026 (fiscal Q2 2026), read by AI.

Insiders

Open-market purchases and sales by executives, board members and major holders

All insider purchases

No open-market purchases in the last 6 months. 8 insiders sold, $27.1M in total.

Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.

  • Loeb GarySale

    10 Nov 2026, EVP & Chief Legal and Complian

    Shares
    400
    Price
    $458.15
    Value
    $183,260
  • Guthart Gary SSale

    4 Nov 2026, Board

    Shares
    10,000
    Price
    $457.34
    Value
    $4.57M
  • Barratt Craig HSale

    4 Nov 2026, Board

    Shares
    1,150
    Price
    $460.00
    Value
    $529,003
Show 41 more
  • Brosius MarkSale

    30 Oct 2026, EVP & Chief Mfg and Supply Cha

    Shares
    63
    Price
    $453.60
    Value
    $28,577
  • Widman FredrikSale

    30 Oct 2026, VP Corporate Controller

    Shares
    5,448
    Price
    $436.06
    Value
    $2.38M
  • Brosius MarkSale

    29 Oct 2026, EVP & Chief Mfg and Supply Cha

    Shares
    61
    Price
    $447.85
    Value
    $27,319
  • Brosius MarkSale

    28 Oct 2026, EVP & Chief Mfg and Supply Cha

    Shares
    61
    Price
    $441.60
    Value
    $26,938
  • Brosius MarkSale

    27 Oct 2026, EVP & Chief Mfg and Supply Cha

    Shares
    61
    Price
    $451.63
    Value
    $27,549
  • Brosius MarkSale

    26 Oct 2026, EVP & Chief Mfg and Supply Cha

    Shares
    61
    Price
    $451.75
    Value
    $27,557
  • Barratt Craig HSale

    23 Oct 2026, Board

    Shares
    1,150
    Price
    $443.80
    Value
    $510,370
  • Widman FredrikSale

    23 Oct 2026, VP Corporate Controller

    Shares
    4,047
    Price
    $453.21
    Value
    $1.83M
  • Wadors Patricia LSale

    23 Oct 2026, SVP Chief Human Resources Officer

    Shares
    1,078
    Price
    $443.80
    Value
    $478,416
  • Guthart Gary SSale

    23 Oct 2026, Board

    Shares
    20,095
    Price
    $451.61
    Value
    $9.08M
  • Widman FredrikSale

    15 Sept 2026, VP Corporate Controller

    Shares
    543
    Price
    $374.44
    Value
    $203,321
  • Brosius MarkSale

    11 Sept 2026, EVP & Chief Mfg and Supply Cha

    Shares
    25
    Price
    $365.79
    Value
    $9,145
  • Brosius MarkSale

    10 Sept 2026, EVP & Chief Mfg and Supply Cha

    Shares
    23
    Price
    $347.66
    Value
    $7,996
  • Brosius MarkSale

    9 Sept 2026, EVP & Chief Mfg and Supply Cha

    Shares
    23
    Price
    $350.20
    Value
    $8,055
  • Brosius MarkSale

    8 Sept 2026, EVP & Chief Mfg and Supply Cha

    Shares
    46
    Price
    $361.23
    Value
    $16,617
  • Brosius MarkSale

    21 Aug 2026, EVP & Chief Mfg and Supply Cha

    Shares
    77
    Price
    $375.57
    Value
    $28,919
  • Brosius MarkSale

    20 Aug 2026, EVP & Chief Mfg and Supply Cha

    Shares
    77
    Price
    $396.37
    Value
    $30,520
  • Brosius MarkSale

    19 Aug 2026, EVP & Chief Mfg and Supply Cha

    Shares
    77
    Price
    $394.26
    Value
    $30,358
  • Brosius MarkSale

    18 Aug 2026, EVP & Chief Mfg and Supply Cha

    Shares
    77
    Price
    $394.00
    Value
    $30,338
  • Brosius MarkSale

    17 Aug 2026, EVP & Chief Mfg and Supply Cha

    Shares
    77
    Price
    $390.67
    Value
    $30,082
  • Guthart Gary SSale

    11 Aug 2026, Board

    Shares
    10,000
    Price
    $400.00
    Value
    $4M
  • Ladd Amy LSale

    11 Aug 2026, Board

    Shares
    72
    Price
    $393.10
    Value
    $28,303
  • Ladd Amy LSale

    10 Aug 2026, Board

    Shares
    400
    Price
    $379.00
    Value
    $151,600
  • Loeb GarySale

    10 Aug 2026, EVP & Chief Legal and Complian

    Shares
    400
    Price
    $379.00
    Value
    $151,600
  • Brosius MarkSale

    31 Jul 2026, EVP & Chief Mfg and Supply Cha

    Shares
    28
    Price
    $351.00
    Value
    $9,828
  • Brosius MarkSale

    30 Jul 2026, EVP & Chief Mfg and Supply Cha

    Shares
    28
    Price
    $346.83
    Value
    $9,711
  • Brosius MarkSale

    29 Jul 2026, EVP & Chief Mfg and Supply Cha

    Shares
    28
    Price
    $360.21
    Value
    $10,086
  • Brosius MarkSale

    28 Jul 2026, EVP & Chief Mfg and Supply Cha

    Shares
    28
    Price
    $365.58
    Value
    $10,236
  • Brosius MarkSale

    27 Jul 2026, EVP & Chief Mfg and Supply Cha

    Shares
    28
    Price
    $344.00
    Value
    $9,632
  • Brosius MarkSale

    12 Jun 2026, EVP & Chief Mfg and Supply Cha

    Shares
    25
    Price
    $414.13
    Value
    $10,353
  • Brosius MarkSale

    11 Jun 2026, EVP & Chief Mfg and Supply Cha

    Shares
    23
    Price
    $412.16
    Value
    $9,480
  • Brosius MarkSale

    10 Jun 2026, EVP & Chief Mfg and Supply Cha

    Shares
    23
    Price
    $424.14
    Value
    $9,755
  • Loeb GarySale

    10 Jun 2026, EVP & Chief Legal and Complian

    Shares
    400
    Price
    $424.14
    Value
    $169,656
  • Brosius MarkSale

    9 Jun 2026, EVP & Chief Mfg and Supply Cha

    Shares
    23
    Price
    $421.13
    Value
    $9,686
  • Brosius MarkSale

    8 Jun 2026, EVP & Chief Mfg and Supply Cha

    Shares
    23
    Price
    $420.12
    Value
    $9,663
  • Jeddi ImanSale

    1 Jun 2026, SVP & GM da Vinci Platforms &

    Shares
    5,625
    Price
    $420.55
    Value
    $2.37M
  • Brosius MarkSale

    22 May 2026, EVP & Chief Mfg and Supply Cha

    Shares
    18
    Price
    $439.80
    Value
    $7,916
  • Brosius MarkSale

    21 May 2026, EVP & Chief Mfg and Supply Cha

    Shares
    18
    Price
    $446.04
    Value
    $8,029
  • Brosius MarkSale

    20 May 2026, EVP & Chief Mfg and Supply Cha

    Shares
    18
    Price
    $440.38
    Value
    $7,927
  • Brosius MarkSale

    19 May 2026, EVP & Chief Mfg and Supply Cha

    Shares
    18
    Price
    $440.70
    Value
    $7,933
  • Brosius MarkSale

    18 May 2026, EVP & Chief Mfg and Supply Cha

    Shares
    18
    Price
    $422.47
    Value
    $7,604

Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.

What happened at Intuitive Surgical

The key events of the last six months from our own data. A click takes you to the matching card.

Sector comparison

714 rated companies in Healthcare

Rank 52 of 714
52/ 714
This company
76
Sector median
53

Categories against the sector median

ProfitabilityMedian of 714 companies89 (median 37)52 above the median
GrowthMedian of 714 companies92 (median 53)39 above the median
FundamentalsMedian of 714 companies97 (median 46)51 above the median
ValuationMedian of 477 companies with a value16 (median 54)38 below the median
StabilityMedian of 714 companies89 (median 67)22 above the median
Capital allocationMedian of 714 companies72 (median 39)33 above the median
Technical analysisMedian of 714 companies63 (median 70)7 below the median
MomentumMedian of 714 companies49 (median 71)22 below the median

The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.

Competitors in Medical (Instruments & Supplies)

The next smaller companies by market value

All 44 Medical (Instruments & Supplies) stocks

ETFs that hold Intuitive Surgical

Held by 110 ETFs on Xetra. Shown per index: the ETF with the largest weight.

ETFWeightCostFund size
Global X Robotics & Artificial Intelligence UCITS ETFXB0T8.47%0.50%€135.35M
Amundi MSCI Robotics & AI UCITS ETF AccGOAI3.64%0.40%€1.14B
iShares Automation & Robotics UCITS ETF2B763.38%0.40%€4.49B
Show 5 more
L&G ROBO Global Robotics and Automation UCITS ETFIROB2.54%0.80%€1.58B
iShares S&P 500 Health Care Sector UCITS ETFQDVG2.48%0.15%€3.27B
Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC2.48%0.12%€1.34B
State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH2.47%0.15%€592.11M
L&G Healthcare Technology & Innovation UCITS ETFXMLH2.36%0.49%€318.39M

Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).

Data status and sources

Score
Daily value of 12 Nov 2026, recalculated nightly
Price
Closing price of 11 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Original filings at the SECReport a data error

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Strong, published since 7 Nov 2026 (in the score history since 31 Jul 2026)
  • Valuation signal Overvalued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
Full disclosures, methodology and data sourcesAll ratings of the last 12 monthsHow the score is calculated

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy